نتایج جستجو برای: erg gene expression

تعداد نتایج: 1609450  

2016
S Weber T Haferlach C Haferlach W Kern

The clinical course of normal karyotype acute myeloid leukemia (CN-AML) is very heterogeneous and partly reflected by specific molecular abnormalities. The most useful markers implicated in prognostication are FLT3 internal tandem duplication (FLT3-ITD), NPM1 mutations (mut), biallelic CEBPAmut and RUNX1mut, with the latter three being now integrated in the updated WHO classification. Beside th...

2015
Sung Han Kim Soo Hee Kim Jae Young Joung Geon Kook Lee Eun Kyung Hong Kyung Min Kang Ami Yu Byung Ho Nam Jinsoo Chung Ho Kyung Seo Weon Seo Park Kang Hyun Lee

OBJECTIVES The aim of this study was to investigate the expression of two commonly altered genes ERG and PTEN in prostate cancer (PC) and evaluate their prognostic significance. Despite conflicting published results, TMPRSS2-ERG gene fusion and PTEN loss are generally considered unfavorable markers for PC progression. MATERIALS AND METHODS Of the 762 prostatic adenocarcinoma specimens obtaine...

2018
Jonathan Shoag Deli Liu Mirjam Blattner Andrea Sboner Kyung Park Lesa Deonarine Brian D. Robinson Juan Miguel Mosquera Yu Chen Mark A. Rubin Christopher E. Barbieri

Nearly 50% of prostate cancers harbor gene fusions that lead to overexpression of the transcription factor ERG, while a mutually exclusive 10% of prostate cancers harbor recurrent mutations in the gene encoding the E3 ubiquitin ligase SPOP. Recent reports suggest that SPOP acts as a ubiquitin ligase for ERG and propose that ERG stabilization is the oncogenic effector of SPOP mutation. Here, we ...

2016
Alexandra M. Blee Shujun Liu Liguo Wang Haojie Huang

Prostate cancer (PCa) that becomes resistant to hormone castration and next-generation androgen receptor (AR)-targeted therapies, called castration-resistant prostate cancer (CRPC), poses a significant clinical challenge. A better understanding of PCa progression and key molecular mechanisms could bring novel therapies to light. One potential therapeutic target is ERG, a transcription factor ab...

2015
Riina-Minna Väänänen Natalia Tong Ochoa Peter J. Boström Pekka Taimen Kim Pettersson

BACKGROUND PCA3 and TMPRSS2-ERG are commonly overexpressed biomarkers in prostate cancer, but reports have emerged demonstrating altered expression also in areas outside the tumour foci in cancerous prostates. Our aim was to measure PCA3 and TMPRSS2-ERG expression systematically in all regions of prostate cross-sections, matching the data to corresponding tissue morphology. METHODS TMPRSS2-ER...

2013
Sudhir Rawal Denise Young Molly Williams Monica Colombo Raghunath Krishnappa Gyorgy Petrovics David G. McLeod Shiv Srivastava Isabell A. Sesterhenn

INTRODUCTION AND OBJECTIVE ERG oncogene fusions (predominantly TMPRSS2-ERG) represent the most common (50-70% frequency) and validated prostate cancer (CaP) genome alteration in the Western countries. A common TMPRSS2-ERG fusion type leads to the androgen dependent tumor cell specific expression of the TMPRSS2-ERG fusion transcript and amino terminally truncated ERG oncoprotein. CaP prevalence ...

2016
Manuel Luedeke Antje E. Rinckleb Liesel M. FitzGerald Milan S. Geybels Johanna Schleutker Rosalind A. Eeles Manuel R. Teixeira Lisa Cannon-Albright Elaine A. Ostrander Steffen Weikert Kathleen Herkommer Tiina Wahlfors Tapio Visakorpi Katri A. Leinonen Teuvo L.J. Tammela Colin S. Cooper Zsofia Kote-Jarai Sandra Edwards Chee L. Goh Frank McCarthy Chris Parker Penny Flohr Paula Paulo Carmen Jerónimo Rui Henrique Hans Krause Sven Wach Verena Lieb Tilman T. Rau Walther Vogel Rainer Kuefer Matthias D. Hofer Sven Perner Mark A. Rubin Archana M. Agarwal Doug F. Easton Ali Amin Al Olama Sara Benlloch Josef Hoegel Janet L. Stanford Christiane Maier

Molecular and epidemiological differences have been described between TMPRSS2:ERG fusion-positive and fusion-negative prostate cancer (PrCa). Assuming two molecularly distinct subtypes, we have examined 27 common PrCa risk variants, previously identified in genome-wide association studies, for subtype specific associations in a total of 1221 TMPRSS2:ERG phenotyped PrCa cases. In meta-analyses o...

2013
Francesca Zammarchi George Boutsalis Luca Cartegni

ERG, a member of the ETS transcription factor family, is frequently overexpressed in prostate cancer as a result of its fusion to the androgen-responsive Tmprss2 gene. Different genomic rearrangements and alternative splicing events around the junction region lead to multiple combination of Tmprss2:ERG fusion transcripts that correlate with different tumor aggressiveness, but their specific fun...

2014
Flávia C. Eguchi Eliney F. Faria Cristovam Scapulatempo Neto Adhemar Longatto-Filho Cleyton Zanardo-Oliveira Sebastião R. Taboga Silvana G. P. Campos

Recurrent gene fusions between the genes TMPRSS2 and ERG have been described in prostate cancer (PCa) and are found in 27% to 79% of radical prostatectomy. This fusion transcription results in ERG overexpression, which can be detected by immunohistochemistry (IHC) and provide a potential diagnostic marker for PCa. Three tissue microarrays (TMAs) containing samples from 98 patients with PCa and ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید